Mehdi Hamadani Named Editor of ASH News Daily 2018
Mehdi Hamadani, MD, has been named the 2018 Editor-in- Chief of ASH News Daily, the official newspaper of the ASH annual meeting. Dr. Hamadani, a lymphoma and bone marrow transplant specialist, is an assistant professor of medicine at the Medical College of Wisconsin’s (MCW’s) Division of Hematology and Oncology.
He also serves as director of the Adult Blood and Marrow Transplant Program at MCW’s Froedtert Hospital in Milwaukee and is associate scientific director of the Center for International Blood and Marrow Transplant Research, a research collaboration between the National Marrow Donor Program/Be The Match® and MCW.
ASH News Daily is produced during the ASH annual meeting and is distributed daily to hotels, shuttle buses, and the convention center. Its four issues, each covering one of the four days of the meeting, feature previews and reviews of Education and Scientific Program sessions, as well as abstract presentations, named lectures, and other events.
Learn more about the publication at hematology.org/ashnewsdaily.
ASH Announces Physician-Scientist Career Development Award Recipients
Congratulations to the recipients of the 2018-2019 ASH Physician-Scientist Career Development Award! This program offers medical students a unique opportunity to conduct hematologic research with experienced ASH members. Starting in July 2018, the students will spend one year conducting laboratory, translational, or clinical research, and will each receive a $42,000 award to cover expenses, salary, and related costs.
This award was granted to:
- Christina Snider, BA, from Cleveland Clinic Lerner College of Medicine, to identify predictive markers of response to therapy in acute myeloid leukemia (AML)
Research mentors: Anjali Advani, MD, and Jaroslaw Maciejewski, MD, PhD
- H. Moses Murdock, BS, Perelman School of Medicine at the University of Pennsylvania, to develop a dynamic risk model for older adults with AML receiving allogeneic stem cell transplantation in first remission
Research mentors: R. Coleman Lindsley, MD, PhD, and Martin Carroll, MD
- Nicholas Jackson Chornenki, Bsc, McMaster University, for translational studies of disseminated intravascular coagulation in sepsis and trauma
Research mentor: Patricia Liaw, MSC, PhD
- Princess Ikemenogo, MHS, BS, Meharry Medical College, to study cerebrovascular disease and cognition in adults with hemoglobin SC
Research mentor: Allison King, MD, MPH, PhD, and Michael DeBaun, MD, MPH
- Robert Schwab, BA, Perelman School of Medicine at the University of Pennsylvania, to engineer oxidized low-density lipoprotein specific regulatory T cells to control and reverse atherosclerosis
Research mentor: Carl June, MD
“The Physician-Scientist Award is an opportunity for ASH to identify up-and-coming talented investigators and encourage them to choose hematology,” said ASH President Alexis Thompson, MD, MPH. “I am proud of this year’s recipients and look forward to following their continued success.”
Blood’s Impact Factor Continues to Rise
Blood has long been an important resource in hematology, and new data reveal its footprint is continuing to grow. The 2017 Clarivate Analytics Journal Citation Report® showed Blood’s impact factor rising from 13.164 to 15.132, demonstrating the continued importance of the journal in hematology and medical science.
The report ranked Blood as the most cited peerreviewed publication in the field of hematology, and 23rd in citations overall, out of 8,964 journals. Blood’s value to the global scientific community is further indicated by its 0.27804 Eigenfactor score, ranking first in hematology and 27th among all scientific journals.
For more from Blood, please visit bloodjournal.org.
ASH Takes Action on World Sickle Cell Day
On June 19, ASH marked World Sickle Cell Day by taking measures to raise awareness of sickle cell disease (SCD) in Africa and elsewhere. In coordination with its SCD Coalition partners, ASH convened a webinar with health experts and members of the media to raise awareness of SCD, its global impact, and efforts to increase SCD screening in newborns.
While SCD is manageable, efforts to treat the disease are complicated by social stigma, lack of awareness, and the spread of misinformation. This year, approximately 300,000 children around the world will be born with SCD. In sub-Saharan Africa, more than half of infants born with SCD will die before their fifth birthday.
ASH founded the SCD Coalition to amplify the voice of the SCD stakeholder community, promote awareness of the disease and its treatment, and improve patient outcomes. The SCD Coalition webinar, “Global Action: Improving Health Outcomes for Sickle Cell Disease,” highlights the extent of the crisis and discusses two recently produced videos promoting newborn screening and combatting prevalent SCD myths in sub-Saharan Africa.
Watch the webinar and learn more about World Sickle Cell Day at scdcoalition.org/global.
ASH Hosts CAR T Briefing on Capitol Hill
On July 10, ASH hosted a briefing on Capitol Hill to educate members of Congress and staff on chimeric antigen receptor (CAR) T-cell therapy and its applications. The Lymphoma Research Foundation and the National Comprehensive Cancer Network co-hosted the briefing on this innovative treatment, which has been approved for certain patients with leukemia and lymphoma who have exhausted all other treatment options.
Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, gave a presentation about the research behind the treatment, while Shannon Maude, MD, PhD, of the Cancer Center at The Children’s Hospital of Philadelphia, and Joseph Alvarnas, MD, of City of Hope in Duarte, California, and chair of the ASH Committee on Practice, presented on the therapy’s use in pediatric and adult populations, respectively. The briefing also included a patient testimonial from Nick Howe, whose lymphoma was successfully treated with CAR Tcell therapy last year.
Learn more about ASH’s advocacy efforts at hematology.org/advocacy.
ASH Announces Collaboration on Von Willebrand Disease Guidelines
New guidelines are underway for the diagnosis and management of von Willebrand disease (vWD), which is the most common bleeding disorder and affects approximately 1 percent of the world’s population.
ASH is collaborating with the International Society on Thrombosis and Haemostasis, the National Hemophilia Foundation, the World Federation of Hemophilia, and the University of Kansas (KU) Medical Center to form two expert panels made up of more than 20 hematologists, patients with vWD, and experts on evidence, appraisal, and guideline development. These panels will identify and prioritize guideline questions, placing high importance on areas in which the development of guidelines could improve care and health outcomes. Once the question formulation is complete, KU Medical Center will conduct a systematic evidence review; the panels will use this information to develop recommendations.
Learn more about the collaboration at hematology.org/vwd-news.